NASDAQ : ENLV
Enlivex Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 2.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.21M |
| Enterprise Value | 14.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.24M |
| Shares Outstanding | 1.24M |
| Shares Change (YoY) | +649.71% |
| Shares Change (QoQ) | +7.64% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 9.78% |
| Float | 485,326 |
Ratios
| Measure | Value |
|---|
| PE Ratio | 0.00 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 0.00 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 119.39 |
| Quick Ratio | 0.19 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 162.86% |
| Return on Assets (ROA) | -0.61% |
| Return on Invested Capital (ROIC) | -0.64% |
| Return on Capital Employed (ROCE) | -0.50% |
| Weighted Average Cost of Capital (WACC) | 1.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $93.82M |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 969.94M |
| Effective Tax Rate | 23.32% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -99.31% |
| 50-Day Moving Average | 10.56 |
| 200-Day Moving Average | 139.32 |
| Relative Strength Index (RSI) | 12.44 |
| Average Volume (20 Days) | 161,521 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 159,295 |
| Short Previous Month | 98,600 |
| Short % of Shares Out | 0.80% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.22M |
| Pretax Income | 4.16B |
| Net Income | 3.19B |
| EBITDA | -23.94M |
| EBIT | -24.22M |
| Earnings Per Share (EPS) | $4,469.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.52M |
| Total Debt | 17.54M |
| Net Cash | -12.03M |
| Net Cash Per Share | -$9.66 |
| Equity (Book Value) | 3.90B |
| Book Value Per Share | 3,705.55 |
| Working Capital | 3.72B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.53M |
| Capital Expenditures | -38,000 |
| Depreciation & Amortization | 278,000 |
| Net Borrowing | 17.93M |
| Free Cash Flow | -15.57M |
| FCF Per Share | -$12.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -649.71% |
| Shareholder Yield | -649.71% |
| Earnings Yield | 251,077.98% |
| FCF Yield | -702.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |